Telbivudine for the treatment of chronic hepatitis B

Drugs of Today

Volumn 43, Issue 5, 2007, Pages 293-304

  Dusheiko, Geoffrey ^a   Danta, Mark ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ALAMIFOVIR; ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; AMDOXOVIR; CLEVUDINE; ELVUCITABINE; EMTRICITABINE; ENTECAVIR; HEPATITIS B ANTIGEN; HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE; NUCLEOSIDE ANALOG; PEGINTERFERON; TELBIVUDINE; TENOFOVIR; VALTORCITABINE; VIRUS DNA;

ANTIVIRAL ACTIVITY; CHRONIC HEPATITIS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CROSS RESISTANCE; DISEASE COURSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG STRUCTURE; DRUG WITHDRAWAL; ENZYME INHIBITION; GLOMERULONEPHRITIS; HEPADNAVIRUS; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; LIVER CIRRHOSIS; LIVER INJURY; MONOTHERAPY; MYOPATHY; MYOSITIS; POLYARTERITIS NODOSA; POLYMERASE CHAIN REACTION; RANDOMIZED CONTROLLED TRIAL; REVIEW; TREATMENT FAILURE; TREATMENT RESPONSE; VIRUS INFECTION; VIRUS REPLICATION; VIRUS RESISTANCE;

ANTIVIRAL AGENTS; CLINICAL TRIALS; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; NUCLEOSIDES; PYRIMIDINONES; VIRUS REPLICATION;

EID: 34447128197     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2007.43.5.1062671     Document Type: Review

References (35)

1. Ganem, D., Prince, A.M. Mechanisms of disease: Hepatitis B virus infection - natural history and clinical consequences. N Engl J Med 2004, 350: 1118-29.
2. Ferrari, C., Penna, A., Bertoletti, A. et al. Cellular immune response to hepatitis B virus-encoded antigens in acute and chronic hepatitis B virus infection. J Immunol 1990, 145: 3442-9.
3. Ferrari, C., Penna, A., Bertoletti, A. et al. Immune pathogenesis of hepatitis B. Arch Virol Suppl 1992, 4: 11-8.
4. Webster, G.J., Reignat, S., Brown, D. et al. Longitudinal analysis of CD8+ T cells specific for structural and nonstructural hepatitis B virus proteins in patients with chronic hepatitis B: Implications for immunotherapy. J Virol 2004, 78: 5707-19.
5. Fattovich, G., Giustina, G., Realdi, G. et al. Long-term outcome of hepatitis B e antigen-positive patients with compensated cirrhosis treated with interferon alfa. Hepatology 1997, 26: 1338-42.
6. Tsukuma, H., Hiyama, T., Tanaka, S. et al. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med 1993, 328: 1797-801.
7. Yang, H.I., Lu, S.N., Liaw, Y.F. et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med 2002, 347: 168-74.
8. Iloeje, U.H., Yang, H.I., Su, J. et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterol 2006, 130: 678-86.
9. Niederau, C., Heintges, T., Lange, S. et al. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med 1996, 334: 1422-7.
10. Iloeje, U.H., Yang, H.I., Su, J. et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterol 2006, 130: 678-86.
11. Dusheiko, G.M., Bowyer, S.M., Paterson, A. et al. Clinical and serological events accompanying changes in hepatitis B viral replication: Case reports. Liver 1985, 5: 77-83.
12. Hoofnagle, J.H., Dusheiko, G.M., Seeff, L.B. et al. Seroconversion from hepatitis B e antigen to antibody in chronic type B hepatitis. Ann Intern Med 1981, 94: 744-8.
13. Perrillo, R.P., Gish, R.G., Peters, M. et al. Chronic hepatitis B: A critical appraisal of cur rent approaches to therapy. Clin Gastroenterol Hepatol 2006, 4: 233-48.
14. Bryant, M.L., Bridges, E.G., Placidi, L. et al. Antiviral L-nucleosides specific for hepatitis B virus infection. Antimicrob Agents Chemother 1901, 45: 229-35.
15. Bryant, M.L., Bridges, E.G., Placidi, L. et al. Anti-HBV specific beta-L-2′-deoxynucleosides. Nucleosides Nucleotides Nucleic Acids 2001, 20: 597-607.
16. Standring, D.N., Bridges, E.G., Placidi, L. et al. Antiviral beta-L-nucleosides specific for hepatitis B virus infection. Antivir Chem Chemother 2001, 12(Suppl. 1): 119-29.
17. Bridges, E. Telbivudine preclinical safety studies suggest minimal risk of chronic toxicity, reproductive toxicity or carcinogenicity. Gastroenterol 2006, 130: A847.
18. Dienstag, J.L. Looking to the future: New agents for chronic hepatitis B. Amer J Gastroenterol 2006, 101: S19-25.
19. Golitsina, N., Danehy, F., Fellows, R. et al. Telbivudine phosphorylation by three enzymes: Implications for anti-hepatitis B virus activity in vitro and in the clinic. Hepatology 2006, 44: 561A.
20. Hu, P., Jiang, J., Wang, H.Y. et al. Single-dose and multiple-dose pharmacokinetics and safety of telbivudine after oral administration in healthy Chinese subjects. J Clin Pharmacol 2006, 46: 999-1007.
21. Lai, C.L., Lim, S.G., Brown, N.A. et al. A dose-finding study of once-daily oral telbivudine in HBeAg-positive patients with chronic hepatitis B virus infection. Hepatol 2004, 40: 719-26.
22. Zhou, X.J., Lloyd, D.M., Chao, G.C. et al. Absence of food effect on the pharmacokinetics of telbivudine following oral administration in healthy subjects. J Clin Pharmacol 2006, 46: 275-81.
23. Zhou, X.J., Lloyd, D.M., Fielman, B.A. et al. Absence of pharmacokinetic drug-drug interaction between telbivudine and lamivudine or adefovir in healthy subjects. J Hepatol 2005, 42: 197-8.
24. Zhou, X.J., Myers, M., Chao, G. et al. Clinical pharmacokinetics of telbivudine, a potent antiviral for hepatitis B, in subjects with impaired hepatic or renal function. J Hepatol 2004, 40: 134.
25. Zhou, X.J., Marbury, T.C., Alcorn, H.W. et al. Pharmacokinetics of telbivudine in subjects with various degrees of hepatic impairment. Antimicrob Agents Chemother 2006, 50: 1721-6.
26. Zhou, X.J., Lim, S.G., Lloyd, D.M. et al. Pharmacokinetics of telbivudine following oral administration of escalating single and multiple doses in patients with chronic hepatitis B virus infection: Pharmacodynamic implications. Antimicrob Agents Chemother 2006, 50: 874-9.
27. Zhou, X.J., Fielman, B.A., Lloyd, D.M. et al. Pharmacokinetics of telbivudine in healthy subjects and absence of drug interaction with lamivudine or adefovir dipivoxil. Antimicrob Agents Chemother 2006, 50: 2309-15.
28. Jia, J.-D., Hou, J.-L., Xu, D.-Z. et al. Two-year results of a phase III comparative trial of telbivudine vs. lamivudine in Chinese patients. J Hepatol 2007, 46 (Suppl. 1): S189.
29. Marcellin, P., Chan, H.L.Y., Lai, C.-L. et al. 76-week follow up of HBeAg-positive chronic hepatitis B patients treated with telbuvidine adefovir or switched from adefovir to telbivudine. J Hepatol 2007, 46 (Suppl. 1): S55.
30. Lai, C.L., Leung, N., Teo, E.K. et al. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen- positive chronic hepatitis B. Gastroenterol 2005, 129: 528-36.
31. Lai, C.L., Gane, E., Liaw, Y.F. et al. Telbivudine (LdT) vs. lamivudine for chronic hepatitis B: First-year results from the international phase III GLOBE trial. Hepatol 2005, 42: 748A.
32. Lai, C.L., Gane, E., Hsu, C.W. et al. Two-year results from the GLOBE trial in patients with hepatitis B: Greater clinical and antiviral efficacy for telbivudine (LdT) vs. lamivudine. Hepatol 2006, 44: 222A.
33. Dibisceglie, A., Lai, C.L., Gane, E. et al. Telbivudine GLOBE trial: Maximal early HBV suppression is predictive of optimal two-year efficacy in nucleoside-treated hepatitis B patients. Hepatol 2006, 44: 230A-1A.
34. Gane, E., Lai, C.L., Min, A. et al. Adefovir salvage therapy for virologic breakthrough in telbuvidine-treated patients from the GLOBE Study. J Hepatol 2007, 46 (Suppl. 1): S187-8.
35. Delaney, W.E., Edwards, R., Colledge, D. et al. Cross-resistance testing of antihepadnaviral compounds using novel recombinant baculoviruses which encode drug-resistant strains of hepatitis B virus. Antimicrob Agents Chemother 2001, 45: 1705-13.